

Est.
1841

YORK
ST JOHN
UNIVERSITY

Chituku, Tsitsi ORCID:

<https://orcid.org/0000-0002-8871-9110>, Jones, Sue and Phillips, Roger (2022) The Development of Locoregional Therapies as a Strategy for Reducing Cervical Cancer Mortality in Low to Middle Income Countries. Authorea.

Downloaded from: <http://ray.yorks.ac.uk/id/eprint/6299/>

The version presented here may differ from the published version or version of record. If you intend to cite from the work you are advised to consult the publisher's version:

<https://www.authorea.com/doi/full/10.22541/au.164873341.16568307>

Research at York St John (RaY) is an institutional repository. It supports the principles of open access by making the research outputs of the University available in digital form. Copyright of the items stored in RaY reside with the authors and/or other copyright owners. Users may access full text items free of charge, and may download a copy for private study or non-commercial research. For further reuse terms, see licence terms governing individual outputs. [Institutional Repository Policy Statement](#)

RaY

Research at the University of York St John

For more information please contact RaY at ray@yorks.ac.uk

The Development of Locoregional Therapies as a Strategy for Reducing Cervical Cancer Mortality in Low to Middle Income Countries.

Tsitsi Chituku¹, Susan Jones², and Roger Phillips³

¹Pilgrim Hospital

²York St John University

³University of Huddersfield School of Applied Sciences

March 31, 2022

Abstract

Early detection concomitant with appropriate treatment intervention for pre-invasive cervical cancer has proved effective in the ‘war on cervical cancer’ in the developed world. Unfortunately, these advances have not been mirrored in the developing world, where incidence and mortality rates are currently approximately 90% of the world’s burden. Due to economic, infrastructure and skilled personnel constraints, the impact of cytology screening as a method for early detection and reducing mortality rates from cervical cancer is lower. Typically, women present with advanced disease that is difficult to treat because of *de novo* and pharmacokinetic resistance. Whilst the HPV vaccine is a welcome development in the fight against cervical cancer, for women who are outside the target age of vaccination, or indeed do not have access to vaccination, screening remains the only form of protection. Current excisional treatments available for cervical dysplasia are effective but have limitations, including increased incidence of obstetric complications and risk of recurrence. This is a particular issue in cases of HIV, which is endemic in the regions most affected by cervical cancer. Therefore, early detection combined with early treatment is an attractive strategy to reduce the number of women presenting with drug resistant disease in developing countries where cytology screening and vaccination services are poorly developed. This review makes the case for developing a locoregional treatment therapy for cervical dysplasia which could be incorporated into a cervical cancer screening strategy in a rural setting within a developing country.

Introduction

Where a woman lives, plus her socioeconomic status, largely determines whether she will develop cervical cancer, how early she presents to healthcare services, and her access to affordable, good quality diagnostic and treatment services ¹. Cervical cancer is preventable because it has a long pre-invasive phase that is easily identified by clinical and histopathological examination. The incidence of this disease is therefore directly related to a nation’s medical infrastructure and the resources available for population-wide screening and the treatment of identified cancers. Prevention and early detection offer the most cost-effective, long-term strategy for the control of cancer, even in low resource settings. Proven and cost-effective interventions for cervical cancer are available, yet access to these are beyond reach for many women in low and middle-income countries (LMIC). These countries have fragmented health systems and are responsible for 86% of the world’s cervical cancer cases ². Shockingly, only 5% of global spending on cancer is directed towards them ³. Without significantly increased screening and preventive treatment services, an estimated 19 million women will die from cervical cancer over the next 40 years ⁴. A key reason for the high mortality rate is the fact that women typically present with late stage or advanced disease. Under these circumstances, treatment is significantly compromised by multiple issues including *de novo* and pharmacokinetic (poor drug

delivery and penetration) resistance. In this review, we discuss the potential benefits that could be gained by use of a ‘screen and treat’ strategy using simple screening methods and locoregional therapies to detect and treat cervical cancers early. The aim would be reducing the number of women in LMIC presenting with advanced, drug resistant disease. It is therefore pertinent to review the magnitude of the problem in LMIC and evaluate the limitations of current treatments for cervical cancer.

The Scale of the Problem in Sub-Saharan Africa

In 2018, there were an estimated 570,000 cases and 311,000 deaths, from cervical cancer worldwide ⁵. It is the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death in women worldwide. Cervical cancer is the most commonly diagnosed cancer in 28 countries and the leading cause of cancer death in 42 countries. The majority of these countries are in Sub-Saharan Africa and South-Eastern Asia, with the highest incidence rate in Swaziland, and the highest mortality rates found in Malawi, Zimbabwe, Guinea, Burkina Faso, and Mali ⁵. In these countries, incidence and mortality rates are seven to 10 times higher than in North America, Australia/New Zealand, Saudi Arabia and Iraq ⁵.

The development of a country can be measured using the Human Development Index (HDI), using its people and their capabilities as opposed to economic growth alone. HDI measures three basic dimensions of human development ⁶ (i) life expectancy at birth (ii) the average number of years of schooling achieved by adults aged 25 years and above and (iii) the gross national income per capita. There appears to be a direct relationship between the HDI of a country and incidence of cervical cancer. When the national incidence burden of cervical cancer is compared the country’s HDI level, cervical cancer makes up to a third of all cancers diagnosed (in both sexes) in many low HDI countries. By comparison, cervical cancer comprises less than 10% of all cancers in very high HDI countries ¹. For this reason cervical cancer can be considered “a case study in health equity” ⁷ based on the unequivocal evidence that cervical cancer is a major problem in LMIC, especially Sub-Saharan countries. Among the most cost-effective strategies according to WHO’s Global Action Plan for the Prevention and Control of Non-Communicable Diseases (2013–20) ⁸. is screening with treatment of pre-cancerous lesions. However, access to these strategies varies depending on where a woman lives, her socioeconomic status and her agency. In 2020, the WHO assembly adopted the Global Strategy for Cervical Cancer Elimination, the aim of which is to eliminate cervical cancer by 2030 through three main approaches: vaccination with a target of 90% of girls fully vaccinated against HPV by the age of 15; screening with a target of 70% of women screened by the ages of 35 and 45; treatment with the target of 90% of women with pre-cancer treated and 90% of women with invasive cancer managed ⁹. This can only be achieved if comprehensive cancer control is implemented in LMICs, including universal access to early diagnosis and accessible treatment for cancer. Therefore, the need for effective strategies to reduce the incidence of cervical cancer, whilst boosting early detection, and the application of treatments (existing and novel) for this disease are imperative in LMIC.

VIA as a Screening Test for Early Detection of Cervical Cancer

The visual inspection with acetic acid (VIA) screening method developed in 2000 has proved to be a valuable tool for cervical cancer screening that developing countries so desperately need. The attractiveness of this simple screening method is based on its ability to be incorporated into a linked ‘screen and treat’ strategy. Integrating screening and treatment that bypasses the need for a protracted wait for screening results and potential loss of follow-up appointments, which is endemic in LMIC countries. Further advantages are the low cost, ability to be performed by trained nurses and lack of need for laboratory facilities or diagnostic equipment. While VIA is more sensitive than cytology with a sensitivity of 76.7% compared to 44.3% for cytology, it is less specific with a specificity of 64.1% compared to 90.6% for cytology¹⁰. Despite this, VIA remains an attractive option, especially in rural areas, where medical and pathology services are not well developed. Unfortunately, to date VIA has been slow in being rolled out in developing countries (especially in the rural areas where it is needed most) as the average screening coverage in Sub-Saharan Africa is only 12.12% ¹¹

Current Treatments for Cervical Dysplasia and their Limitations

Treatments for pre-cancerous cervical lesions developed over the past five decades, are responsible for reducing the incidence and mortality of cervical cancer in developed countries over the same period of time^{12,13} (Kitchener et al., 2006; Peto et al., 2004). Essentially, treatment uses ablative methods such as cryotherapy, laser ablation and electrocautery. Alternatively, excisional methods such as loop electrosurgical excision procedure (LEEP) (or large loop excision of the transformation zone (LLETZ)) and cold knife cone biopsy (CKC) (also known as conization) can be used, depending on the extent and severity of the lesion. Ablative methods destroy the precancerous cells in the transformation zone by necrosis, with no anaesthetic required, and no tissue is removed. Excisional methods involve removal of the precancerous lesion under either local or general anaesthetic, together with a margin of healthy tissue, which can be sent for histological evaluation. LEEP and CKC are performed by an experienced clinician, generally an obstetrician/gynaecologist who can recognize and manage complications, and in a facility where surgical back-up is available if required¹⁴. This limits the use of excisional methods as treatments in LMICs¹⁴. Whilst these surgical procedures remove the neoplasia, they do not target the cause of these lesions, which is persistent HPV infection. Recurrence rates for cervical intraepithelial neoplasia (CIN) after treatment is between 5-26%^{15,16}.

There are advantages and disadvantages associated with each of the techniques used, for example there is an increase in major and minor bleeding with LEEP compared to CKC, however there is a decreased risk of major infection with LEEP compared with CKC¹⁷. CKC has the lowest recurrence rate of CIN 2+ when compared with LEEP and cryotherapy¹⁷. However, CKC is associated with other complications such as major infection (including pelvic inflammatory disease) and increased risk of premature labour¹⁷. A meta-analysis on perinatal mortality and adverse pregnancy outcomes showed that cold knife conization, laser conization and radical diathermy were associated with a significantly increased risk of peri-natal mortality, pre-term delivery, low birthweight^{18,19}, premature rupture of membranes and caesarean section¹⁸. While the literature is not consistent about effects of excisional therapy on fertility, and a meta-analysis²⁰ found no evidence to support an effect on fertility outcomes, there was evidence that excisional therapy increased the risk of a second trimester miscarriage possibly due to cervical incompetence after large excisions.

A further complication in LMIC is that while excisional therapy is effective treatment for cervical dysplasia in immunocompetent patients, it seems to be effective only in slowing progression to cervical cancer in HIV positive women. The recurrence rates for women with HIV are much higher than for HIV negative women, even in the Highly Active Anti-retroviral Therapy (HAART) era, with studies showing recurrence rates of up to 63%²¹⁻²⁴. Fruchter et al., reported that 90% of HIV-infected women with CD4 counts less than 200 cells/mm³ developed recurrent dysplasia at 3 years²¹. While antiretroviral therapy may delay the recurrence of HPV-related disease in HIV positive women, immune restoration on HAART is insufficient to clear HPV because HPV DNA persists in patients on HAART²⁵. Furthermore, the incidence of invasive cervical cancer has remained constant since the introduction of HAART²⁶, and treatment with HAART has failed to eradicate CIN in many HIV-infected women²⁷. As a result, definitive management with hysterectomy has been advocated for eradication of cervical dysplasia in HIV positive women.

Recent data suggests that most CIN2 lesions regress spontaneously, particularly in young women, under 30 years²⁸. This means that the reclassification of CIN2 and CIN3 as high grade squamous intraepithelial lesion (HSIL) has huge implications for many women, especially young women in their reproductive years. There is a possibility that spontaneously regressing lesions could be classified as high grade lesions that warrant treatment and the attendant increased risks of reproductive morbidity^{18,17}. Taken together, there is a clear case for developing locoregional medical therapies in LMIC based on the “screen and treat” approach. Simple screening using VIA combined with application of the treatment directly to the surface of the cervix, would circumvent the issues of delayed diagnosis, low follow-up rates, the high risk of infection or adverse pregnancy outcomes attendant with current practice.

Chemoresistance in Cervical Cancer Therapy

Currently, invasive cervical cancer is treated with surgery or radiation combined with a platinum-based chemotherapy. The most effective chemotherapeutic agent used in cervical cancer treatment is Cisplatin, which can be used either as a single agent or in combination with other therapeutic agents, e.g. 5-Fluorouracil

²⁹. More advanced stages of cervical cancer are treated by chemotherapy, including metastatic disease, as well as patients with persistent, or recurrent disease. Unfortunately these patients typically have a poor prognosis because cancer cells can develop resistance to the chemotherapy agents ³⁰. One of the main obstacles in the treatment of late-stage cervical cancer is resistance which develops to chemotherapeutic agents ³¹. An increase in the number of available chemotherapeutic agents has resulted in increased resistance in cancer cells as more exposure to medications makes tumour cells more prone to developing drug resistance which subsequently leads to widespread metastasis ²⁹.

Cisplatin interacts with DNA molecules to form cross-linked DNA “adducts” which in turn activate several downstream molecular pathways including p53 and MAPK, ultimately resulting in apoptosis²⁹. Chemo-resistance arises in cancer cells via the downregulation of tumour suppressors and the stabilization or activation of cell survival factors ³² including increased DNA repair, decreased uptake of drug into the tumour cells and increased inactivation of drug ²⁹. These mechanisms lead to less apoptosis in cancer cells, resulting in unchecked tumour replication and spread of malignancy ^{33,34}.

Most women in Africa present with late-stage cervical cancer when chemo-radiotherapy becomes the only option for curative or palliative treatment. A recent study of 2760 patients from 11 African countries found that 65.8% had stage III-IV disease ³⁵. In Zimbabwe, 76% of women present at the later stages of the disease³⁷. Patients who present with late stage disease have poorer outcomes. The 5-year overall survival for stage III-IV cervical cancer as determined from nine African registries was 20.5%³⁶ compared to 50.3% for stage I-II cervical cancer³⁵. Moreover, it is estimated that only 8% of The International Federation of Gynaecologists and Obstetricians (FIGO) stage I-III patients in Africa receive guideline-adherent care due to lack of access to treatment facilities. While an estimated 55% of new of cancer diagnoses in Africa could be treated by radiotherapy, there are no available radiation facilities in 26 of 54 African countries³⁸. In countries where they do exist, they are inaccessible to most patients because they are either located in tertiary institutions, are non-functional or poorly maintained, or they are available only in the private sector at a cost out of reach for most patients ³⁸. Late-stage disease presentation in addition to poor access to radiotherapy means that therapeutic options for advanced presentations are increasingly limited to chemotherapy alone, further compounding the problem of chemoresistance.

Overcoming drug resistance is an important approach in cancer research, and various agents including phytochemicals have been investigated as potential bioactive agents in the arsenal of the war against cancer. For example, curcumin sensitizes cervical cancer cells to paclitaxel treatment and inhibits pathways involved in cellular proliferation and survival *in vivo* ³⁹. It also plays a role in the reversal of resistance to cisplatin in cervical cancer cells⁴⁰. An indirect but logical way of mitigating the effects of multi drug resistance in cervical cancer is to focus on early detection of cervical lesions and early intervention to prevent progression to late-stage disease. This strategy has a three-fold advantage. Firstly, targeting early lesions which have not breached the basement membrane and are contained to the epithelium offer a pharmacokinetic advantage for a loco-regional therapy as drug will be penetrating a thin layer of cells with less chance of pharmacokinetic drug resistance developing. Secondly, treating the disease at the early stages negates the use of chemotherapy and hence abrogating the factors that lead to the development of chemoresistance. Thirdly, and more pertinent to LMIC treating early-stage disease removes the financial and resource burden associated with treating late-stage disease, thus making the disease eminently more treatable with rapid and better patient outcomes.

The concept for developing a loco-regional therapy for cervical cancer in LMIC would focus treatment directly onto the pre-neoplastic lesion leading to local control of the disease and effectively preventing recurrence. It would be particularly applicable in the case of HIV positive women for whom treatment is associated with high recurrence rates, and for whom treatment resistance is a problem. In a country like Zimbabwe where HIV prevalence rates are around 15%⁴¹, this would apply to a significant proportion of women. Loco-regional therapy as part of a “screen and treat” strategy would also reduce the need for yearly cervical screens following a diagnosis and treatment of high-grade cervical dysplasia (CIN2+). Importantly, any treatment that negates the use of excisional or ablative methods would be beneficial as it would also reduce the incidence of obstetric

complications, in women of reproductive age. There is a clear rationale for developing loco-regional therapies for treating cervical cancer, particularly in the rural areas of LMIC where access or travel to medical facilities can be problematical.

Precedence for Locoregional Therapies to treat Cervical Dysplasia

It is well established that cervical cancer is caused by persistent infection with one or more of the oncogenic human papilloma virus (HPV) genotypes for a period longer than 2 years^{42,43}. HPV infection is common worldwide, with a lifetime cumulative risk of greater than 80%⁴⁴. To date only a few drug-based locoregional therapies have been developed for HPV infection which are approved for use in clinical practice, however, none of them are licensed for the management of cervical dysplasia. These therapies target either the molecular virology of HPV infection, the neoplasia itself, or the immune response to the virus (or indeed all three modalities) leading to viral clearance or lesion elimination⁴⁵. Strategies that target the HPV virus aim to reduce the rate of recurrence by focusing on the cause of the lesions and thereby have an impact on the amount of latent and subclinical HPV DNA rather than just removing the neoplasia⁴⁵. There is precedence in the literature for locoregional therapies to treat cervical dysplasia either indirectly by targeting the HPV infection or directly by treating the cancer. Details of treatments so far trialed have been reviewed extensively elsewhere⁴⁶. Briefly, topical therapies studied so far have included immune modulators such as imiquimod⁴⁷⁻⁴⁹, antiproliferative therapies such as 5Fluorouracil (5-FU)^{50,51}, antivirals such as Cidofovir⁵², Lopinavir and Ritonavir, a combination oral HIV protease inhibitor (Lopimune)⁵³⁻⁵⁵, Vidarabine^{56,57} and Terameprocol^{57,58} and hormonal drugs for treatment of CIN 1 such as Dehydroepiandrosterone (DHEA)⁵⁹. In addition, other approaches include herbal/non-pharmacologic therapies such as green tea⁶⁰, praneem, the seed extract of *Azadirachta indica*⁶¹, glycyrrhizinic acid⁶² and curcuma (turmeric). Of all these, the randomized trials of Imiquimod, 5-FU, and Cidofovir have had the most promising results⁴⁶. These will be discussed in more detail in the ensuing review.

Designing a Cervico-vaginal drug delivery system

The cervical and vaginal ecosystem is complex due to the balance between the conflicting need for protection against infection and allowing entry of sperm to the upper genital tract. As such, there is a pH gradient from the acidic vaginal canal at pH 3.8 - 4.5⁶³⁻⁶⁵ to the alkaline cervical mucus at pH 7.0⁶⁶. The accessibility of the cervix and presence of a good blood supply makes vaginal drug delivery an ideal potential target for a locoregional therapy. In addition, this route avoids both hepatic first pass metabolism as the absorbed drugs enter directly into the systemic circulation and gastrointestinal enzymatic degradation associated with the oral route⁶⁷. Vaginal drug delivery systems in current use comprise liquid forms including foams, douches and irrigations, semi-solid forms such as creams, gels and ointments, and solid forms in the form of pessaries, rings and films⁶⁸. All these have limited efficacy depending on their residence time at the genitourinary tract⁶⁹. A vaginal drug delivery system designed for locoregional therapy should ideally, distribute uniformly and retain the drug at the administered the site of action for a prolonged period⁶⁹. This depends upon the properties of the delivery system, and vaginal physiology. Factors relating to vaginal physiology include the volume, viscosity and pH of vaginal fluid and the thickness and porosity of the epithelial layer which in turn varies with age and menstrual cycle⁷⁰. The self-cleansing action of the vaginal tract^{71,72} results in a decrease in the therapeutic effects of these delivery systems due to reduced drug bioavailability⁷³. Furthermore, the protective mechanism of the genitourinary tract further limits residence time, making it necessary for multiple and frequent drug applications for effective treatment⁶⁹. This would be further impacted by the additional challenge of patient compliance if repeated applications are required for treatment.

Pessaries in the form of tablets or suppositories provide a sustained release of the drug as they gradually dissolve⁶⁸. The bioavailability of the drug depends upon its residence time in the vaginal canal⁶⁹. Creams are typically emulsions whereas gels are three-dimensional hydrophilic polymers made up of long, disordered chains with reversible cross-links⁷⁴. A potential issue with using both creams and gels is that they do not provide an exact dose and they can be messy, uncomfortable and cause leakage⁷⁵. Patients generally tolerate gels better than other dosage forms⁷⁶.

Over the last decade, muco-adhesive and *in situ* gelling formulations have been used to increase the residence time of liquid vaginal drug formulations at the site of action⁷⁷. Muco-adhesive polymers such as polyacrylic acid-based Carbomers interact with mucus proteins in the vaginal cavity by forming weak hydrogen bonds or disulphide bonds with thiol groups, thereby prolonging the formulation residence time at the action site⁷³. *In-situ* gelling systems are typically present in a sol-state at room temperature, which describes a type of colloid with small particulate solids dispersed within a liquid, before administration. They subsequently undergo a sol-gel transition in response to temperature, pH change or the presence of ions upon contact with biological fluids or mucous membranes in the vaginal canal, forming a gel. The gel releases the loaded drug in a controlled manner, resulting in a formulation with reduced administration frequency, ease of administration and therefore improved patient compliance and comfort⁷⁷. They also include solid formulations such as polymeric matrices and films that undergo fast hydration in biological fluids to form a gel with controlled release properties. Nanosystems can also be loaded onto a muco-adhesive *in-situ* gelling vehicle. The intimate interface between the mucus and gel enables transfer of the nanosystems to the site of action on the vaginal mucosa⁷⁸.

Locoregional therapy for cervical lesions

As mentioned previously, none of the drug-based locoregional therapies so far developed for HPV infection are licensed for the management of cervical dysplasia. There have, however, been some promising results from trials of locoregional therapy for cervical lesions. We will now discuss in greater detail some of these studies involving 5-Flourouracil, Cidofovir and more recently, Lopimune, including some of the advantages, limitations, and the potential for clinical use of the various therapies.

5-Flourouracil

5-flourouracil (5-FU) is an antimetabolite analogue of the pyrimidine uracil, with a fluorine atom at the C-5 position in place of hydrogen⁷⁹. Intracellularly, the fluoropyrimidine is converted into fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine triphosphate (FUTP) which become mis-incorporated into RNA and DNA⁸⁰. Furthermore, FdUMP inhibits the enzyme thymidylate synthase by competitively binding to its active site thereby blocking binding of the normal substrate dUMP and inhibiting dTMP synthesis^{81,82}. Because of its cytotoxicity, 5-FU is used widely as a chemotherapeutic agent in cancer treatment. Topical 5-FU cream is used for treatment of intraepithelial neoplasia of the skin and off-license treatment of HPV related lesions including genital warts, vulvar intraepithelial neoplasia and vaginal intraepithelial neoplasia^{83,84}.

The safety profile of 5-FU was established in a randomized controlled study involving 90 women with HPV-associated vaginal and vulval lesions. Women who used prophylactic topical 5-FU at a dosage of 2 g once every two weeks after ablative therapy, were significantly less likely to develop recurrent lesions than controls⁸⁵. In a later study where the drug was used for vaginal HPV-associated lesions continuously over five to seven days, or periodically once a week for 10 weeks, dose and duration dependent chronic mucosal ulceration developed in 8.2% of subjects⁸⁶. In a separate study, 5-FU was used as an adjunctive treatment following excisional therapy for CIN 2-3 in HIV positive patients in order to prevent recurrence⁵⁰. A dosage of 2 g of 5% 5-FU cream was self-administered using vaginal applicators at bedtime once every two weeks for six months. The recurrence rate in the treatment arm was 28% compared to 47% in the observation arm and there was a statistically significant prolonged time to recurrence in the treatment arm compared to the observation group. Once again vaginal 5-FU at this dosage and interval was extremely well tolerated, with minimal morbidity in HIV-infected women with CIN⁵⁰.

Another trial investigated intravaginal 5% 5-FU vs standard-of-care observation in young women aged 18 – 29 years with CIN 2 with the primary outcome of disease regression at six months after the diagnosis of CIN 2⁵¹. Dual contraception with condoms plus one either oral, intravaginal, injectable, implantable, or intrauterine device was required for the 5-FU group because of its potential teratogenic effects. The established dosage of 2 g of topical 5% 5-FU cream was applied once every two weeks for a period of 16 weeks (a total of eight doses) which is standard with other studies⁸⁷⁻⁹⁰. This was inserted into the vagina

at night using a vaginal applicator, and a tampon placed per vagina overnight to keep the cream in-situ, and then removed in the morning. Disease regression was demonstrated in 84% of women in the 5-FU group compared to 52% of women in the observation group, and after six months the treated group was twice as likely to be both HPV negative and clear of neoplasia⁵¹.

As described above, one of the drawbacks of using a vaginal cream based locoregional therapy is the inability to control the precise site of application and the duration of drug action, resulting in local and systematic side effects^{91,92}. In an effort to circumvent this problem, 5-FU was incorporated into a one-way release bilaminar bio-adhesive drug delivery system⁹³ which was placed directly on the cervix using a device applicator, and kept *in situ* for 24 hours, after which time it was removed using threads that were attached to it for that purpose, releasing a once only dose of 20 mg. This study involved 104 patients with CIN 1 and 2, where the control arm received the delivery system loaded with a placebo. The device was spontaneously expelled in four patients before the 24 hours was up, and 41% of patients in the drug arm developed erythema of the cervix compared to only 8% in the placebo group. More importantly, there was no difference in remission of CIN between drug and placebo groups⁹³. The authors concluded that despite the effectiveness of the delivery system, one application of 5-FU was not effective in the treatment of CIN due to inadequate dosage.

In a separate bid to achieve better therapeutic efficacy and increased patient compliance, 5-FU was formulated in a vaginal gel with thermosensitive and muco-adhesive properties in order to increase residence time at the cervix⁹⁴. The drug was incorporated as its inclusion complex in a 1:1 molar ratio with either β -cyclodextrin or hydroxypropyl- β -cyclodextrin in order to increase its aqueous solubility and to achieve the complete release of 5-FU from the gel and this did not affect the gelling temperature significantly⁹⁴. The muco-adhesive polymer HPMC conferred favorable thermosensitive *in situ* gelling properties and complexation to cyclodextrins resulted in a ten-fold increase in cytotoxicity against HeLa cells⁹⁴. This was also confirmed by the enhanced release profile of 5-FU through complexation⁹⁴. All this suggesting that formulating an anticancer drug in a muco-adhesive, thermosensitive gel in complexation with cyclodextrins can increase its anticancer activity resulting in lower doses and reduced unwanted side effects through controlled release and prolonged residence time at the administration site. The disadvantages of 5-FU are its potential for teratogenic effects in its intravenous form in women of child-bearing age and for causing cervical mucosal ulceration⁸⁶ thereby potentially placing women at increased risk of sexually transmitted infections⁵¹.

Cidofovir

Cidofovir is an acyclic nucleoside phosphonate with a broad-spectrum activity against DNA viruses. It competitively inhibits the incorporation of deoxycytidine triphosphate into viral DNA by viral DNA polymerase, causing a disruption in chain elongation⁹⁵. Cidofovir's mechanism of action and its selectivity for HPV-transformed cells is dependent on their inability to respond to DNA damage, rather than having a direct anti-HPV effect. Viral oncoproteins E6 and E7, in HPV infected cells cause deregulation of cell cycle control, making these cells are more susceptible to DNA damage than normal keratinocytes⁹⁶. Treatment with Cidofovir causes cell death by apoptosis. Induction of apoptosis in HPV infected cells by Cidofovir was associated with accumulation of the tumour suppressor proteins p53 and pRb and the cyclin-dependent kinase inhibitor p21/WAF-1⁹⁷.

Systemic exposure of Cidofovir after vaginal application is low. This was observed in a trial of nine women with CIN2+ treated with 3 g of 2% Cidofovir gel administered in a cervical cap and applied directly to the cervix, once per week for five or ten hours, over a period of three weeks. Very low plasma concentrations were reached when compared with intravenous administration, at the approved dose⁹⁸ indicating that the drug stays at the desired site of action on the cervix and works locally with limited systemic absorption and thereby minimizing the risk of unwanted systemic side effects. In another study, 48 women with biopsy-proven CIN2+ were treated with either three applications of 3 ml of 2% Cidofovir gel in a cervical cap or a placebo for four hours, six weeks before conization. Biopsy results from the excised cones showed resolution of CIN in 60.8% in the Cidofovir group compared to 20% in the placebo group. In addition, there were no systemic toxicity or cervico-vaginal side effects of Cidofovir compared to the placebo. However, Cidofovir failed to eradicate HPV infection⁵². Contrastingly, in a separate study by Snoeck et al., 15 women had 3 g

of 1% Cidofovir gel applied on the cervix three times on alternate days by a gynaecologist using colposcopy for an average of 17 days. The results from the cone biopsies taken after more prolonged treatment with Cidofovir showed a complete response in seven of the 15 patients and in four of these seven patients, PCR results showed resolution of HPV infection. Once again there was no toxicity observed in the normal tissue and the treatment was well tolerated⁹⁹. These studies support selectivity of Cidofovir against HPV induced epithelial proliferation compared to normal epithelium. In five of the 15 patients there was a limited response in the superficial epithelial layers, two patients did not respond, and one patient downgraded from CIN3 to CIN1. The partial response is likely due to poor bioavailability of the drug at the deeper epithelial layers indicating the need to modify the dosage or formulation of the drug in order to reach the deeper layers⁹⁹

Lopimune

Lopimune is an oral HIV Protease Inhibitor (PI) comprising of Lopinavir and Ritonavir. Pre-clinical and early trial results in the locoregional therapy for CIN have been promising⁵³. PIs have anti-cancer activity against HPV-related cervical disease, in addition to their anti-HIV action⁵⁴ and Lopinavir is the most effective. It exerts its activity by blocking the HPV16 E6 protein from producing proteasomal degradation of p53 in cultured cervical carcinoma cells¹⁰⁰ and upregulation of the antiviral protein, ribonuclease L, and this has been subsequently confirmed in HPV16 E6/E7 immortalized keratinocytes⁵⁴ and at doses used for oral HIV therapy, which are more than ten times the concentration achieved in cervico-vaginal fluid¹⁰¹, Lopinavir shows high selective toxicity for E6/E7 expressing cells¹⁰². Lopimune is formulated as an oral gelatine capsule for HIV treatment.

In a single-arm non-randomized proof-of-concept clinical trial done in Kenya, 23 high risk HPV positive women with CIN2+ used Lopimune capsules as a self-applied twice daily vaginal pessary for a period of two weeks⁵³. Cytology was done at 12 weeks which was confirmed by histology, and showed that in 77.8% there was either complete resolution of dysplasia or there had been a change from CIN2+ to CIN1/2, and HPV was no longer detected in 52.2% of women. Treatment with Lopimune was well tolerated, and nausea was the only reported adverse reaction. Systemic exposure of the drug was limited, reaching plasma levels of 10ng/ml which is much less than the levels of 2.8-6.6 μgml^{-1} that is reported with oral delivery in HIV therapy¹⁰¹. However, this could be partly due to the sub-optimal dosage used in the trial, which resulted in some women showing a transient change in HPV status or cytology which reverted back to baseline after 12 weeks. The authors surmised that since HPV is DNA-based and therefore more stable than RNA-based HIV, it is possible to repeat treatment multiple times with less chance of developing resistance, as a way of addressing treatment failure. In contrast to 5 FU, Lopimune is a non-cytotoxic drug which can be safely used in women of child-bearing age. Additionally, it is currently licensed for systemic treatment of HIV infected pregnant women and children¹⁰³.

Potential New Locoregional Treatments for Pre-Invasive Cervical Cancer

The anticancer drug EO9 (or Apaziquone) is an indolequinone based bioreductive drug that requires activation by cellular oxidoreductases to generate DNA damaging species. Its mechanism of action, which centres on the enzyme NQO1 reducing EO9 to reactive species, has been extensively reviewed elsewhere alongside its pre-clinical and clinical history^{104,105}. Briefly, EO9 failed clinical trials when administered intravenously primarily because rapid pharmacokinetic elimination prevented sufficient drug reaching the tumour to induce an anti-tumour effect. It was argued that whilst its poor pharmacokinetic properties were not suitable for systemic drug administration, they would paradoxically be ideal for the locoregional treatment of pre-invasive cancers¹⁰⁶. In the case of non-muscle invasive bladder cancer (NMIBC), intravesical administration would circumvent the drug delivery problem and any drug reaching the systemic circulation would be rapidly cleared thereby reducing the risk of systemic toxicity. In a phase I/II pilot study involving 12 patients with low risk NMIBC, eight complete responses were recorded¹⁰⁷ with similar complete response rates (67%) reported in phase II studies¹⁰⁸. Furthermore, follow up studies reported good two-year recurrence free rates^{109,110} suggesting that the long-term response rates were good in comparison to standard of care treatments for NMIBC. Whilst the results of phase III clinical trials were disappointing (due largely to changes in clinical trial design from phase II to phase III¹⁰⁵), these studies have nevertheless established

the principle that compounds with poor systemic pharmacokinetic properties can have clinical efficacy when used in a loco-regional setting. In the context of pre-invasive cervical cancers, NQO1 is overexpressed in squamous cell carcinoma of the cervix and CINs compared to normal cervical epithelia¹¹¹ suggesting that EO9 would be a promising candidate for the locoregional treatment of pre-invasive cervical cancer.

Conclusion

Cervical cancer is endemic in sub-Saharan Africa and other parts of the developing world, that are least prepared to deal with a high burden of disease. The current methods of screening and treatment for cervical dysplasia and invasive cancer have clearly not achieved the same results in the developing world as they have done in the developed world towards reducing the burden of this disease. With up to nine out of 10 cervical cancer cases and deaths occurring in LMICs² and the disease being the most commonly diagnosed cancer in 28 of these countries and the leading cause of cancer death in 42 countries⁵, it has become imperative that innovative ways of dealing with the problem of cervical cancer in sub-Saharan Africa and the developing world are found. Ideally this innovative approach would address the limitations posed by the current methods of treatment for cervical dysplasia, as well as being able to be integrated into the existing VIA screen and treat strategy used in this region, which negates the need for trained clinicians and expensive medical infrastructure. An ideal locoregional therapy for HPV-induced cervical lesions to be used in this setting would be a cytotoxic anticancer agent which would target the pre-neoplastic lesion with high selectivity for diseased epithelium and non-toxic to normal tissue and low systemic absorption. The anticancer agent must be readily available, safe to use in women of child-bearing age and effective. The formulation would be self-administered with increased residence time at the cervix and therefore require a minimum number of applications, for it to be acceptable to patients. In this growing area of research, developing a drug-based locoregional treatment for cervical dysplasia which can be administered at the time of screening by a nurse or even by the patient themselves and with no requirement for specialized equipment, could prove to be the game-changer that sub-Saharan Africa so desperately needs in the fight against cervical cancer.

DECLARATIONS

Authors' contributions

TC designed, wrote and prepared the article with SJ and RMP contributing to the conceptual design, reviewing and critical appraisal.

Availability of data and materials

Not applicable.

Financial support and sponsorship

None.

Conflicts of interest

There are no conflicts of interest.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Copyright

© The Author(s) 2022.

REFERENCES

1. Ginsburg, O. *et al.* The global burden of women’s cancers: a grand challenge in global health. *Lancet* **389** , 847–860 (2017).
2. Ferlay, J. *et al.* GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase. No. 11 [Internet]. *Lyon, France: International Agency for Research on Cancer*. **11** , <http://globocan.iarc.f> (2013).
3. Farmer, P. *et al.* Expansion of cancer care and control in countries of low and middle income: A call to action. *The Lancet***376** , 1186–1193 (2010).
4. Tsu, V. & Jerónimo, J. Saving the World’s Women from Cervical Cancer. *N. Engl. J. Med.* **374** , 2509–2511 (2016).
5. Bray, F. *et al.* Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA. Cancer J. Clin.* **68** , (2018).
6. UNDP. What is Human Development? *UNDP Hum. Dev. Reports*(2017).
7. Wittet, S. & Tsu, V. Cervical cancer prevention and the Millennium Development Goals. *Bull. World Health Organ.* **86** , 488–490 (2008).
8. WHO. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. *World Heal. Organ.* 102 (2013). doi:978 92 4 1506236
9. WHO. *Global strategy to accelerate the elimination of cervical cancer as a public health problem and its associated goals and targets for the period 2020 – 2030* . *United Nations General Assembly***2** , (2020).
10. Gaffikin, L., Blumenthal, P. D., McGrath, J. & Chirenje, Z. M. Visual inspection with acetic acid for cervical-cancer screening: Test qualities in a primary-care setting. *Lancet* **353** , 869–873 (1999).
11. Yimer, N. B. *et al.* Cervical cancer screening uptake in Sub-Saharan Africa: a systematic review and meta-analysis. *Public Health* **195** , (2021).
12. Kitchener, H. C., Castle, P. E. & Cox, J. T. Chapter 7: Achievements and limitations of cervical cytology screening. *Vaccine* **24** , (2006).
13. Peto, J., Gilham, C., Fletcher, O. & Matthews, F. E. The cervical cancer epidemic that screening has prevented in the UK. *Lancet (London, England)* **364** , 249–56 (2004).
14. Maza, M. *et al.* Cervical Precancer Treatment in Low- and Middle-Income Countries: A Technology Overview. *J Glob Oncol*(2016). doi:10.1200/JGO.2016.003731
15. Gonzalez, C. D. I. *et al.* Recurrence of dysplasia after loop electrosurgical excision procedures with long-term follow-up. *Am. J. Obstet. Gynecol.* **184** , 315–321 (2001).
16. Soutter, W. P., Sasieni, P. & Panoskaltsis, T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. *Int. J. Cancer* **118** , 2048–55 (2006).
17. Santesso, N. *et al.* Systematic reviews and meta-analyses of benefits and harms of cryotherapy, LEEP, and cold knife conization to treat cervical intraepithelial neoplasia. *International Journal of Gynecology and Obstetrics* **132** , 266–271 (2016).
18. Kyrgiou, M. *et al.* Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: Systematic review and meta-analysis. *Lancet* **367** , 489–498 (2006).
19. Arbyn, M. *et al.* Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. *BMJ* **337** , a1284 (2008).
20. Kyrgiou, M. *et al.* Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. *Bmj* **349** , g6192–g6192 (2014).

21. Fruchter, R. G. *et al.* Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. *Obstet. Gynecol.* **87** , 338–44 (1996).
22. Maiman, M. *et al.* Recurrent cervical intraepithelial neoplasia in human immunodeficiency virus-seropositive women. *Obstet. Gynecol.* **82** , 170–174 (1993).
23. Paramsothy, P. *et al.* Abnormal vaginal cytology in HIV-infected and at-risk women after hysterectomy. *J. Acquir. Immune Defic. Syndr.* **35** , 484–491 (2004).
24. Petry, K. U. *et al.* Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. *Int. J. Cancer* **57** , 836–840 (1994).
25. Heard, I., Palefsky, J. M. & Kazatchkine, M. D. The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. *Antiviral Therapy* **9** , 13–22 (2004).
26. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. *J. Natl. Cancer Inst.* **92** , 1823–30 (2000).
27. Heard, I. *et al.* High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV-positive women. *J. Acquir. Immune Defic. Syndr.* **39** , 412–8 (2005).
28. Tainio, K. *et al.* Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. *Bmj* k499 (2018). doi:10.1136/bmj.k499
29. Jalil, A., Wert, J., Farooq, A. & Ahmad, S. Overcoming drug resistance in cervical cancer: Chemosensitizing agents and targeted therapies. in *Overcoming Drug Resistance in Gynecologic Cancers* 195–205 (Elsevier Inc., 2021). doi:10.1016/b978-0-12-824299-5.00010-1
30. Zhu, H. *et al.* Molecular mechanisms of cisplatin resistance in cervical cancer. *Drug Design, Development and Therapy* **10** , (2016).
31. Song, W., Jiang, R. & Zhao, C. M. Role of integrin-linked kinase in multi-drug resistance of human gastric carcinoma SGC7901/DDP cells. *Asian Pacific J. Cancer Prev.* **13** , (2012).
32. Ali, A. Y. *et al.* Molecular determinants of ovarian cancer chemoresistance: New insights into an old conundrum. *Ann. N. Y. Acad. Sci.* **1271** , (2012).
33. Amable, L. Cisplatin resistance and opportunities for precision medicine. *Pharmacological Research* **106** , (2016).
34. Siddik, Z. H. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. *Oncogene* **22** , (2003).
35. Sengayi-Muchengeti, M. *et al.* Cervical cancer survival in sub-Saharan Africa by age, stage at diagnosis and Human Development Index: A population-based registry study. *Int. J. Cancer* **147** , (2020).
36. Sung, H. *et al.* Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA. Cancer J. Clin.* **71** , (2021).
37. Chinombe, N., Sebata, N. L., Ruhanya, V. & Matarira, H. T. Human papillomavirus genotypes in cervical cancer and vaccination challenges in Zimbabwe. *Infect. Agent. Cancer* **9** , 16 (2014).
38. Mahantshetty, U. *et al.* Incidence, Treatment and Outcomes of Cervical Cancer in Low- and Middle-income Countries. *Clin. Oncol.* **33** , (2021).
39. Sreekanth, C. N., Bava, S. V., Sreekumar, E. & Anto, R. J. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. *Oncogene* **30** , 3139–3152 (2011).
40. Roy, M. & Mukherjee, S. Reversal of resistance towards cisplatin by curcumin in cervical cancer cells. *Asian Pacific J. Cancer Prev.* **15** , 1403–1410 (2014).

41. UNAIDS. Epidemiological Fact Sheet on HIV and AIDS - Zimbabwe. (2013).
42. Goodman, A. HPV testing as a screen for cervical cancer. *Bmj* **350** , h2372–h2372 (2015).
43. Munoz, N. & Bosch, F. X. The causal link between HPV and cervical cancer and its implications for prevention of cervical cancer. *Bull. Pan Am. Health Organ.* **30** , 362–377 (1996).
44. Dunne, E. F. *et al.* Prevalence of HPV infection among females in the United States. *JAMA* **297** , 813–819 (2007).
45. Stern, P. L. *et al.* Therapy of human papillomavirus-related disease. *Vaccine* **30** , (2012).
46. Desravines, N., Miele, K., Carlson, R., Chibwesa, C. & Rahangdale, L. Topical therapies for the treatment of cervical intraepithelial neoplasia (CIN) 2–3: A narrative review. *Gynecologic Oncology Reports* (2020). doi:10.1016/j.gore.2020.100608
47. Grimm, C. *et al.* Treatment of cervical intraepithelial neoplasia with topical imiquimod: A randomized controlled trial. *Obs. Gynecol* **120** , 152–159 (2012).
48. Pachman, D. R. *et al.* Randomized clinical trial of imiquimod: An adjunct to treating cervical dysplasia. *Am. J. Obstet. Gynecol.* **206** , (2012).
49. Lin, C.-T. *et al.* Topical imiquimod treatment for human papillomavirus infection in patients with and without cervical/vaginal intraepithelial neoplasia. *Taiwan. J. Obstet. Gynecol.* **51** , 533–8 (2012).
50. Maiman, M. *et al.* Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: a randomized trial. *Obstet. Gynecol.* **94** , 954–61 (1999).
51. Rahangdale, L. *et al.* Topical 5-fluorouracil for treatment of cervical intraepithelial neoplasia 2: A randomized controlled trial. *Am. J. Obstet. Gynecol.* **210** , (2014).
52. Van Pachterbeke, C. *et al.* Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study. *Gynecol. Oncol.* **115** , 69–74 (2009).
53. Hampson, L. *et al.* A Single-Arm, Proof-Of-Concept Trial of Lopimune (Lopinavir/Ritonavir) as a Treatment for HPV-Related Pre-Invasive Cervical Disease. *PLoS One* **11** , (2016).
54. Batman, G. *et al.* Lopinavir up-regulates expression of the antiviral protein ribonuclease L in human papillomavirus-positive cervical carcinoma cells. *Antivir. Ther.* **16** , 515–525 (2011).
55. Lahiri, C. D. *et al.* Oral lopinavir use and human papillomavirus infection in HIV-positive women. *Journal of Acquired Immune Deficiency Syndromes* **70** , e63–e66 (2015).
56. Niwa, K. *et al.* Topical vidarabine or 5-fluorouracil treatment against persistent HPV in genital (pre)cancerous lesions. *Oncol. Rep.* (2003). doi:10.3892/or.10.5.1437
57. Okamoto, A. *et al.* Combination therapy with podophyllin and vidarabine for human papillomavirus positive cervical intraepithelial neoplasia. *Oncol. Rep.* (1999). doi:10.3892/or.6.2.269
58. Khanna, N. *et al.* Phase I/II clinical safety studies of terameprocol vaginal ointment. *Gynecol. Oncol.* (2007). doi:10.1016/j.ygyno.2007.08.074
59. Suh-Burgmann, E., Sivret, J., Duska, L. R., Del Carmen, M. & Seiden, M. V. Long-term administration of intravaginal dehydroepiandrosterone on regression of low-grade cervical dysplasia - A pilot study. *Gynecol. Obstet. Invest.* (2003). doi:10.1159/000068953
60. Ahn, W. S. *et al.* Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. *Eur. J. Cancer Prev.* (2003). doi:10.1097/00008469-200310000-00007

61. Shukla, S. *et al.* Elimination of high-risk human papillomavirus type HPV16 infection by ‘Praneem’ polyherbal tablet in women with early cervical intraepithelial lesions. *J. Cancer Res. Clin. Oncol.* (2009). doi:10.1007/s00432-009-0617-1
62. Valencia, M. H., Pacheco, A. C., Quijano, T. H., Giron, A. V. & Lopez, C. V. Clinical response to glycyrrhizinic acid in genital infection due to human papillomavirus and low-grade squamous intraepithelial lesion. *Clin. Pract.* (2011). doi:10.4081/cp.2011.e93
63. Cohen, L. Influence of pH vaginal discharges. *Obstet. Gynecol. Surv.* (1970). doi:10.1097/00006254-197008000-00026
64. Kelly, K. G. Tests on Vaginal Discharge. *Clin. Methods Hist. Phys. Lab. Exam.* (1990).
65. Redondo-Lopez, V., Cook, R. L. & Sobel, J. D. Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. *Rev. Infect. Dis.* (1990). doi:10.1093/clinids/12.5.856
66. Correa, C. H. M., Mattos, A. L. G. & Ferrari, A. N. In situ variation of cervical mucus pH during exposure to atmospheric air. *Brazilian J. Med. Biol. Res.* (2001). doi:10.1590/S0100-879X2001000600011
67. Layek, B. & Das, S. Chitosan-based nanomaterials in drug delivery applications. in *Biopolymer-Based Nanomaterials in Drug Delivery and Biomedical Applications* (2021). doi:10.1016/b978-0-12-820874-8.00001-4
68. Krishna, S., Ashok, V. & Chatterjee, A. A Review on Vaginal Drug Delivery Systems. *International Journal of Biology, Pharmacy and applied Sciences* **1** , 152–167 (2012).
69. Bilensoy, E., Rouf, M. A., Vural, I., Şen, M. & Hincal, A. A. Mucoadhesive, thermosensitive, prolonged-release vaginal gel for clotrimazole: β -cyclodextrin complex. *AAPS PharmSciTech* **7** , (2006).
70. Deshpande, T., Shinde, R. & Pawar, Y. Mucoadhesive Drug Delivery System - Vaginal. in *Drug Delivery Systems - A Review* (ed. Gothoskar, A. V) 160–181 (e-book, 2012).
71. David Woolfson, A. Intravaginal Drug Delivery Technologies. in (2002). doi:10.1201/9780203910337.pt8
72. Deshpande, A. A., Rhodes, C. T. & Danish, M. Intravaginal drug delivery. *Drug Dev. Ind. Pharm.* **18** , (1992).
73. Lacey, C. J. N. Therapy for genital human papillomavirus-related disease. *Journal of Clinical Virology* **32** , (2005).
74. das Neves, J. & Bahia, M. F. Gels as vaginal drug delivery systems. *International Journal of Pharmaceutics* **318** , (2006).
75. Hussain, A. & Ahsan, F. The vagina as a route for systemic drug delivery. *Journal of Controlled Release* **103** , (2005).
76. Hardy, E., Jiménez, A. L., De Pádua, K. S. & Zaneveld, L. J. D. Women’s preferences for vaginal antimicrobial contraceptives III: Choice of a formulation, applicator, and packaging. *Contraception* **58** , (1998).
77. Vignani, B. *et al.* Recent advances in the development of in situ gelling drug delivery systems for non-parenteral administration routes. *Pharmaceutics* **12** , (2020).
78. Pall, A., Mahajan, B. B., Puri, K. P. S. & Gupta, R. R. Therapeutic Evaluation of Intralesional 5% 5-Fluorouracil in Condyloma Acuminata. *J. Dermatol.* **31** , (2004).
79. Longley, D. B., Harkin, D. P. & Johnston, P. G. 5-Fluorouracil: Mechanisms of action and clinical strategies. *Nature Reviews Cancer* (2003). doi:10.1038/nrc1074
80. Longley, D. B., Harkin, D. P. & Johnston, P. G. 5-Fluorouracil: Mechanisms of action and clinical strategies. *Nature Reviews Cancer* **3** , (2003).

81. Sommer, H. & Santi, D. V. Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5-fluoro-2'-deoxyuridylate and methylenetetrahydrofolate. *Biochem. Biophys. Res. Commun.* (1974). doi:10.1016/0006-291X(74)90601-9
82. Santi, D. V., McHenry, C. S. & Sommer, H. Mechanism of Interaction of Thymidylate Synthetase with 5-Fluorodeoxyuridylate. *Biochemistry* (1974). doi:10.1021/bi00700a012
83. Stanley, M. Chapter 17: Genital human papillomavirus infections—current and prospective therapies. *J. Natl. Cancer Inst. Monogr.* **6** , 117–124 (2003).
84. van de Nieuwenhof, H. P., van der Avoort, I. A. M. & de Hullu, J. A. Review of squamous premalignant vulvar lesions. *Critical Reviews in Oncology/Hematology* **68** , 131–156 (2008).
85. Krebs, H. B. Prophylactic topical 5-fluorouracil following treatment of human papillomavirus-associated lesions of the vulva and vagina. *Obstet. Gynecol.* **68** , (1986).
86. Krebs, H. B. & Helmkamp, B. F. Chronic ulcerations following topical therapy with 5-fluorouracil for vaginal human papillomavirus-associated lesions. *Obstet. Gynecol.* **78** , (1991).
87. Edwards, L. *et al.* Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. *Arch. Dermatol.* **134** , (1998).
88. Garland, S. M., Waddell, R., Mindel, A., Denham, M. & McCloskey, J. C. An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women. *Int. J. STD AIDS* **17** , (2006).
89. Stockfleth, E. *et al.* Topical Polyphenon(r) E in the treatment of external genital and perianal warts: A randomized controlled trial. *Br. J. Dermatol.* **158** , (2008).
90. Tatti, S. *et al.* Sin catechins, a defined green tea extract, in the treatment of external anogenital warts: A randomized controlled trial. *Obstet. Gynecol.* **111** , (2008).
91. Pride, G. L. & Chuprevich, T. W. Topical 5-fluorouracil treatment of transformation zone intraepithelial neoplasia of cervix and Vagina. *Obstet. Gynecol.* (1982).
92. Barten, G. [Local treatment of cervical intraepithelial neoplasia with a 5 percent fluorouracil ointment]. *Zentralbl. Gynakol.*(1987).
93. Sidhu, H. K. *et al.* A randomised controlled trial evaluating a novel cytotoxic drug delivery system for the treatment of cervical intraepithelial neoplasia. *BJOG An Int. J. Obstet. Gynaecol.*(1997). doi:10.1111/j.1471-0528.1997.tb11034.x
94. Bilensoy, E., Cırpanlı, Y., Şen, M., Doğan, A. L. & Çalıř, S. Thermosensitive mucoadhesive gel formulation loaded with 5-Fu: Cyclodextrin complex for HPV-induced cervical cancer. *J. Incl. Phenom. Macrocycl. Chem.* **57** , 363–370 (2007).
95. Lea, A. P. & Bryson, H. M. Cidofovir. *Drugs* **52** , 225–230 (1996).
96. De Schutter, T., Andrei, G., Topalis, D., Naesens, L. & Snoeck, R. Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage. *BMC Med. Genomics* (2013). doi:10.1186/1755-8794-6-18
97. Andrei, G., Snoeck, R., Schols, D. & De Clercq, E. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. *Oncol. Res.* (2000). doi:10.3727/096504001108747855
98. Bossens, M. *et al.* Safety and tolerance of cidofovir as a 2% gel for local application in high-grade cervical intraepithelial neoplasia: A phase 1 investigation. *Int. J. Clin. Pharmacol. Ther.* (2018). doi:10.5414/CP203126

99. Snoeck, R., Noel, J. C., Muller, C., De Clercq, E. & Bossens, M. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). *J. Med. Virol.* **60** , (2000).
100. Hampson, L., Kitchener, H. C. & Hampson, I. N. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. *Antivir. Ther.* **11** , 813–825 (2006).
101. Kwara, A. *et al.* Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. *Clin. Infect. Dis.* **46** , 719–25 (2008).
102. Zehbe, I. *et al.* Lopinavir shows greater specificity than zinc finger ejecting compounds as a potential treatment for human papillomavirus-related lesions. *Antiviral Res.* **91** , 161–166 (2011).
103. Pasley, M. V., Martinez, M., Hermes, A., D’Amico, R. & Nilius, A. Safety and efficacy of lopinavir/ritonavir during pregnancy: A systematic review. *AIDS Reviews* **15** , (2013).
104. Phillips, R. M., Hendriks, H. R. & Peters, G. J. EO9 (Apaziquone): From the clinic to the laboratory and back again. *British Journal of Pharmacology* **168** , 11–18 (2013).
105. Phillips, R. M., Hendriks, H. R., Sweeney, J. B., Reddy, G. & Peters, G. J. Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer. *Expert Opin. Drug Metab. Toxicol.* **13** , 783–791 (2017).
106. Phillips, R. M. Prospects for bioreductive drug development. *Expert Opin. Investig. Drugs* **7** , 905–928 (1998).
107. Puri, R. *et al.* Phase I/II Pilot Study of Intravesical Apaziquone (EO9) for Superficial Bladder Cancer. *J. Urol.* (2006). doi:10.1016/j.juro.2006.06.047
108. van der Heijden, A. G. *et al.* Phase II Marker Lesion Study With Intravesical Instillation of Apaziquone for Superficial Bladder Cancer: Toxicity and Marker Response. *J. Urol.* (2006). doi:10.1016/j.juro.2006.06.007
109. Jain, A. *et al.* Response of Multiple Recurrent TaT1 Bladder Cancer to Intravesical Apaziquone (EO9): Comparative Analysis of Tumor Recurrence Rates. *Urology* **73** , (2009).
110. Hendricksen, K. *et al.* Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. *World J. Urol.* **27** , (2009).
111. Ma, Y. *et al.* NQO1 overexpression is associated with poor prognosis in squamous cell carcinoma of the uterine cervix. *BMC Cancer* **14** , 414 (2014).